Home
Account
Research Tools
Educate
Contribute
News
Sectors
Premium
About Us
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
Earnings
Dividend
Management Changes
M&A
Analyst
FDA
IPO
About Us
Contact Us
Advertise With Us
Editorial Staff
Terms and Conditions
Privacy Policy
iStock Rating
F
Details...
Enter Symbol
Genmab A/S Dkk (OTCBB: GNMSF)
Sector: Medical
Current Price :
$36.15
52 Week Low
$7.30
52 Week High
$36.15
Company
Overview
Research Notes
Company Profile
Competitors
Community
Stock Sentiment
Whisper Estimates
Enter Estimates
Message Board
Analysis
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Press Releases
Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
Genmab Announces Financial Results for the First Quarter of 2013
Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocytic Leukemia
Daratumumab Receives Breakthrough Therapy Designation From US Food and Drug Administration
Arzerra First Quarter 2013 Net Sales Figures
Passing of Genmab A/S' Annual General Meeting
Genmab Announces Final US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit
Daratumumab Granted Fast Track Designation From U.S. Food and Drug Administration
Arzerra Receives Approval in Japan
Genmab 2012 Annual Report
Genmab Announces Sale of Manufacturing Facility to Baxter
Arzerra Fourth Quarter and Full Year 2012 Net Sales Figures
Major Shareholder Announcement
Genmab Unveils a New Antibody Technology Platform: HexaBody
Genmab Reaches Third Milestone in Lundbeck Collaboration
Genmab Reaches Milestone in DuoBody Platform Collaboration With Janssen
New Preliminary Efficacy Data for Daratumumab Presented at ASH
Genmab Announces DuoBody Platform Collaboration With Kyowa Hakko Kirin
CORRECTION: Genmab Announces Financial Results for the First Nine Months of 2012 and Improves 2012 Financial Guidance
Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance
Arzerra Third Quarter 2012 Net Sales Figures
Major Shareholder Announcement
Capital Increase in Genmab as a Result of Execution of a Private Placement to Johnson & Johnson Development Corporation
Agreement for Daratumumab Receives Antitrust Clearance
Additional Details Concerning Issue of Shares to Johnson & Johnson Development Corporation as Part of the Daratumumab Agreement
Genmab Enters Worldwide Agreement With Janssen for Daratumumab
Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance
Arzerra Second Quarter 2012 Net Sales Figures
Genmab A/S to Ring The NASDAQ Stock Market Closing Bell
Genmab Enters DuoBody Technology Collaboration
Milestone Triggered in Connection With Filing of New Drug Application in Japan for Arzerra
Genmab Announces Financial Results for the First Quarter 2012
New Drug Application for Arzerra Submitted in Japan
Passing of Genmab A/S' Annual General Meeting
Arzerra First Quarter 2012 Net Sales Figures
Genmab Revised Financial Calendar for 2012
Genmab A/S Summons Annual General Meeting
Genmab Announces Patent Settlement Agreement for Ofatumumab
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Genmab 2011 Annual Report
Genmab Reaches Second Milestone in Lundbeck Collaboration
Arzerra Fourth Quarter and Full Year 2011 Net Sales Figures
Genmab Announces Progress With DuoBody(TM) Platform
Genmab Announces Progress With Lundbeck Collaboration
Genmab Announces Preliminary Safety and Efficacy Data for Daratumumab
Genmab's Financial Calendar for 2012
Genmab Announces Appeal of US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit
Genmab Announces US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit
Genmab Announces Top-Line Phase II Results for Ofatumumab Combined with Chemotherapy in Second Line Aggressive Lymphoma
Genmab Announces Zalutumumab Update
Arzerra First Quarter 2011 Net Sales Figures
Passing of Genmab A/S' Annual General Meeting
Genmab A/S Summons Annual General Meeting
Arzerra Fourth Quarter and Full Year 2010 Net Sales Figures
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##